| Literature DB >> 29317766 |
Ung Jeon1, Samel Park1, SangHo Park1, Eun-Young Lee1, Hyo-Wook Gil2.
Abstract
Patients who attempt intentional suicide suffer from physical or emotional stress. This situation might be an important factor that causes takotsubo cardiomyopathy. We retrospectively investigated the clinical features of Takotsubo cardiomyopathy in patients with acute poisoning. This study included patients who were admitted from January 2010 to December 2015 because of intentional poisoning by ingestion. Among these patients, we selectively collected data of patients who underwent an echocardiogram. We divided the patients into three groups according to the echocardiogram; the non-cardiomyopathy group, the global hypokinesia group, and the takotsubo cardiomyopathy group. One hundred forty-seven patients were analyzed in this study. One hundred thirty-one patients had normal cardiac function without regional wall motion abnormality. Global hypokinesia was observed in five patients. The overall incidence of takotsubo cardiomyopathy was 7.5% (11/147). Levels of cardiac enzymes including CK-MB, Troponin T, a marker of cardiac muscle ischemia, were higher in the global hypokinesia group and the takotsubo cardiomyopathy group compared with the non-cardiomyopathy group. The most commonly consumed poison was organophosphate in the takotsubo cardiomyopathy group. In conclusion, takotsubo cardiomyopathy may be one of the cardiac complications in patients who attempt suicide by consuming a poison.Entities:
Mesh:
Substances:
Year: 2018 PMID: 29317766 PMCID: PMC5760562 DOI: 10.1038/s41598-017-18478-5
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1Flow diagram of patient selection.
Characteristics of patients according to the pattern of cardiomyopathy.
| Non-cardiomyopathy (n = 131) | Global hypokinesia (n = 5) | Takotsubo cardiomyopathy (n = 11) | p-value | |
|---|---|---|---|---|
| Sex (M/F) | 73/58 | 4/1 | 5/6 | 0.455 |
| Age | 67.39 ± 14.72 | 69.00 ± 10.00 | 63.45 ± 14.03 | 0.425 |
| Underlying disease | ||||
| DM | 21(16.0%) | 1(20.0%) | 1(9.1%) | 0.741 |
| Hypertension | 62(47.3%) | 2(40.0%) | 5(45.5%) | 1.000 |
| Poisoning | 0.547 | |||
| Pesticide | ||||
| Herbicide | ||||
| Glyphosate | 17 | 1 | 1 | |
| Glufosinate | 24 | 1 | 4 | |
| Glyphosate + Glufosinate | 3 | 0 | 0 | |
| Paraquat | 12 | 1 | 0 | |
| Other herbicides | 6 | 0 | 0 | |
| Insecticide | ||||
| Organophosphate | 8 | 1 | 4 | |
| Pyrethroid | 4 | 0 | 0 | |
| Organophosphate + other insecticide | 7 | 0 | 1 | |
| Carbamate | 4 | 0 | 0 | |
| Other insecticides | 5 | 0 | 0 | |
| Fungicide | 1 | 0 | 1 | |
| Medical drug | 27 | 1 | 0 | |
| pesticide + medical drug | 3 | 0 | 0 | |
| others | 7 | 0 | 0 | |
| Unknown | 3 | 0 | 0 | |
| Medical complication | ||||
| Mechanical ventilation | 62 (47.3%) | 2 (40.0%) | 10 (90.9%) | 0.012 |
| Acute kidney injury | 52 (39.7%) | 4 (80.0%) | 7 (63.6%) | 0.065 |
| Medication during hospitalization | ||||
| Vasopressor | 52 (39.7%) | 3 (60.0%) | 9 (81.8%) | 0.011 |
| Atropine | 23 (17.6%) | 1 (20.0%) | 4 (36.4%) | 0.259 |
| Mortality | 14 (10.7%) | 0 (0.0%) | 0 (0.0%) | 0.772 |
Comparison of laboratory among the three groups.
| Non-cardiomyopathy (n = 131) | Global hypokinesia (n = 5) | Takotsubo cardiomyopathy (n = 11) | p-value | |
|---|---|---|---|---|
| Ejection fraction | 64.98 ± 4.91 | 47.20 ± 5.59 | 34.27 ± 6.20 | < |
| Heart rate | 87.42 ± 20.69 | 77.00 ± 16.81 | 104.55 ± 16.35 |
|
| White blood cell count | 13732 ± 5697 | 13164 ± 9745 | 15302 ± 6810 | 0.657 |
| Hospital days | 16.11 ± 12.86 | 11.80 ± 5.63 | 24.55 ± 11.10 |
|
| Hemoglobin (g/dL) | 13.84 ± 1.86 | 12.28 ± 3.85 | 13.27 ± 1.60 | 0.123 |
| Platelet | 252.92 ± 101.05 | 175.00 ± 30.14 | 243.09 ± 48.20 |
|
| Albumin (mg/dL) | 4.08 ± 0.57 | 3.92 ± 0.59 | 4.10 ± 0.62 | 0.806 |
| Glucose (mg/dl) | 162.76 ± 64.86 | 154.00 ± 53.49 | 165.27 ± 62.37 | 0.982 |
| AST (IU/L) | 43.11 ± 53.61 | 38.20 ± 17.34 | 47.64 ± 44.12 | 0.575 |
| ALT (IU/L) | 29.05 ± 53.75 | 19.40 ± 7.89 | 26.64 ± 21.73 | 0.951 |
| LDH (IU/L) | 314.98 ± 152.76 | 445.80 ± 290.20 | 352.09 ± 194.65 | 0.550 |
| Urea nitrogen (mg/dL) | 18.00 ± 9.16 | 22.60 ± 6.20 | 15.15 ± 5.03 | 0.101 |
| Creatinine (mg/dL) | 1.02 ± 0.60 | 1.58 ± 0.79 | 0.76 ± 0.17 |
|
| Calcium (mg/dL) | 8.86 ± 1.29 | 8.24 ± 0.17 | 8.47 ± 0.91 |
|
| Phosphorus (mg/dL) | 3.63 ± 1.54 | 4.06 ± 2.33 | 3.22 ± 1.12 | 0.564 |
| Uric acid | 5.40 ± 2.15 | 5.84 ± 2.72 | 3.72 ± 1.28 |
|
| Sodium (mEq/L) | 139.87 ± 4.48 | 142.00 ± 5.83 | 141.00 ± 3.35 | 0.642 |
| Potassium (mEq/L) | 3.97 ± 0.73 | 4.36 ± 1.02 | 3.86 ± 1.00 | 0.525 |
| Chloride (mEq/L) | 102.08 ± 5.33 | 106.60 ± 6.95 | 104.64 ± 4.76 | 0.108 |
| pH | 7.35 ± 0.11 | 7.32 ± 0.14 | 7.36 ± 0.13 | 0.934 |
| PaCO2 (mmHg) | 35.93 ± 9.88 | 31.80 ± 5.81 | 39.78 ± 14.62 | 0.475 |
| PaO2 (mmHg) | 85.31 ± 41.40 | 83.00 ± 30.24 | 89.97 ± 66.67 | 0.948 |
| HCO3 (mEq/L) | 20.11 ± 5.31 | 16.88 ± 5.31 | 21.82 ± 4.80 | 0.266 |
| Base excess | −5.479 ± 6.50 | −9.24 ± 7.25 | −3.55 ± 5.60 | 0.386 |
| Creatine kinase | 822.56 ± 4970.86 | 695.80 ± 870.92 | 122.82 ± 65.47 | 0.203 |
| Peak CK-MB* | 55.54 ± 82.46 | 68.60 ± 66.05 | 63.45 ± 44.55 | 0.123 |
| Peak troponin T* | 0.1197 ± 0.4172 | 0.1646 ± 0.2635 | 0.2218 ± 0.1694 |
|
| Peak NT-proBNP* | 1265.44 ± 1937.08 | 371.40 ± 41.71 | 9728.19 ± 10061.51 |
|
| CRP | 20.80 ± 56.31 | 60.16 ± 100.43 | 10.85 ± 21.65 | 0.374 |
AST, aspartate transaminase; ALT, alanine transaminase; LDH, lactate dehydrogenase; CK-MB, creatine kinase-MB; NT-proBNP, N-terminal prohormone of brain natriuretic peptide.
Individual characteristics of patients with takotsubo cardiomyopathy.
| Age/sex | Poisoning drug | Initial echocardiograpic findings | Initial EF (%) | ECG findings | Peak Pro-BNP (pg/ml) | Peak CK-MB (U/L) | Peak Troponin T (ng/ml) | F/U EF (%) | F/U days of echo | Coronary evaluation (CAG or cardiac angio CT) |
|---|---|---|---|---|---|---|---|---|---|---|
| 50/F | Organophospate | Mid ventricular type | 40 | T wave inversion | 4113 | 97 | 0.342 | 58 | 8 | NA |
| 79/M | Organophospate | Mid ventricular type | 31 | Deep T wave inversion | 745.6 | 49 | 0.230 | 64 | 8 | No significant coronary stenosis |
| 54/F | Organophospate | Basal type | 35 | No ST-T change | 13061 | 35 | 0.086 | 51 | 6 | NA |
| 51/F | Organophospate | Mid ventricular type | 26 | ST depression | 8678 | 79 | 0.118 | 57 | 7 | NA |
| 54/F | Glyphosate | Apical type | 25 | T wave inversion | 180.5 | 62 | 0.419 | 58 | 7 | No significant coronary stenosis |
| 80/M | Glufosinate | Apical type | 38 | Deep T wave inversion | 12749 | 21 | 0.113 | 65 | 60 | NA |
| 43/F | Glufosinate | Basal type | 45 | ST depression | 472.8 | 44 | 0.454 | 62 | 8 | No significant coronary stenosis |
| 71/F | Glufosinate | Apical type | 35 | ST elevation Deep T wave inversion | 18877 | 55 | 0.043 | 66 | 18 | No significant coronary stenosis |
| 71/M | Glufosinate | Apical type | 30 | Deep T wave inversion | - | 36 | 0.185 | 60 | 60 | No significant coronary stenosis |
| 53/M | Organophospate | Basal type | 32 | No ST-T change | 32193 | 179 | 0.544 | 71 | 20 | NA |
| 81/M | Organophospate + pyrethroid | Apical type | 40 | ST elevation Deep T wave inversion | 6212 | 60 | 0.341 | 55 | 8 | NA |
EF: ejection fraction, ECG: electrocardiography, F/U: follow up, CAG: coronay angiography, CT: computer tomography, NA: not available.
Figure 2Serial change in Troponin T versus time lag after ingestion in the takotsubo cardiomyopathy group.